IT Solutions
Limited access to data 'could increase potential of science software'
Jan 07 2011
Researchers at the University of Southern California (USC) looked into how restricted access to previous findings for use in modern science software can impact on production costs and time to market.
Perhaps intuitively, they found costs are increased when previous research findings are made less available to those working on new pharmaceutical and clinical solutions.
However, they claim that life expectancy would increase and more products would be developed if tighter restrictions were imposed on data.
By extending controls in the US from the current standard period of five years to that used in Europe, which is around ten years, the scientists claim generic drug manufacturers could be dissuaded from focusing on cheaper versions of existing therapies.
This, they say, would increase costs but also drive innovation of entirely new solutions, rather than cheaper duplication of existing drugs.
USC claims to be a leader in an "ever-flattening world" thanks to its high proportion of international students compared with other US academic institutions.
Digital Edition
Lab Asia 31.2 April 2024
April 2024
In This Edition Chromatography Articles - Approaches to troubleshooting an SPE method for the analysis of oligonucleotides (pt i) - High-precision liquid flow processes demand full fluidic c...
View all digital editions
Events
Apr 28 2024 Montreal, Quebec, Canada
May 05 2024 Seville, Spain
InformEx Zone at CPhl North America
May 07 2024 Pennsylvania, PA, USA
May 14 2024 Oklahoma City, OK, USA
May 15 2024 Birmingham, UK